REG - ConvaTec Group PLC - Result of AGM

ConvaTecAnnouncement

12/05/2022 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220512:nRSL3391La&default-theme=true

RNS Number : 3391L  ConvaTec Group PLC  12 May 2022

ConvaTec Group Plc

 

Results of Annual General Meeting

 

 

Reading, United Kingdom (12 May 2022) - Poll Result

ConvaTec Group Plc ("ConvaTec") held its Annual General Meeting today
("AGM"). The results of the poll held in relation to the resolutions proposed
at the AGM are set out below

 

                                                                                     For (see note 2)                     Against (see note 2)                            Votes Total               % of ISC Voted  Votes Witheld
 Resolution                                                                          No of shares              %          No of Shares                       %
 1       Receive Annual Report and Accounts                                                1,827,980,026       99.99%                 138,955                0.01%              1,828,118,981       89.85%                  2,678,250
 2       Approve the Directors' Remuneration Report                                        1,310,074,242       72.51%           496,566,511                  27.49%             1,806,640,753       88.80%                24,156,478
 3       Declare Final Dividend                                                            1,828,471,889       99.87%              2,318,530                 0.13%              1,830,790,419       89.98%                        6,812
 4       Re-elect John McAdam as a director                                                1,785,547,176       97.61%             43,742,972                 2.39%              1,829,290,148       89.91%                  1,507,083
 5       Re-elect Karim Bitar as a director                                                1,824,546,868       99.66%              6,234,317                 0.34%              1,830,781,185       89.98%                      16,046
 6       Re-elect Margaret Ewing director                                                  1,808,325,168       98.77%             22,443,302                 1.23%              1,830,768,470       89.98%                      28,761
 7       Re-elect Brian May as a director                                                  1,713,823,773       94.03%           108,742,705                  5.97%              1,822,566,478       89.58%                  8,230,753
 8       Re-elect Sten Scheibye as a director                                              1,824,824,180       99.68%              5,944,289                 0.32%              1,830,768,469       89.98%                      28,762
 9       Re-elect Heather Mason as a director                                              1,812,618,794       99.01%             18,149,676                 0.99%              1,830,768,470       89.98%                      28,761
 10      Re-elect Professor Constantin Coussios as a director                              1,811,236,685       98.93%             19,521,954                 1.07%              1,830,758,639       89.98%                      38,592
 11      Elect Jonny Mason as a director                                                   1,819,579,146       99.39%             11,187,969                 0.61%              1,830,767,115       89.98%                      30,116
 12      Elect Kim Lody as a director                                                      1,824,822,794       99.68%              5,812,573                 0.32%              1,830,635,367       89.98%                    161,864
 13      Elect Sharon O'Keefe as a director                                                1,824,954,544       99.68%              5,812,573                 0.32%              1,830,767,117       89.98%                      30,114
 14      Re-appoint Deloitte LLP as auditors                                               1,828,465,498       99.95%                 830,907                0.05%              1,829,296,405       89.91%                  1,500,826
 15      Authorise the Directors to agree the auditors' remuneration                       1,830,098,448       99.96%                 671,868                0.04%              1,830,770,316       89.98%                      26,915
 16      Authorise political donations and political expenditure                           1,814,389,000       99.12%             16,165,069                 0.88%              1,830,554,069       89.97%                    241,662
 17      Authorise allotment of shares                                                     1,737,684,352       94.92%             93,082,507                 5.08%              1,830,766,859       89.98%                      30,372
 18      Renew the Scrip Dividend Scheme.                                                  1,830,739,805       100.00%                  22,649               0.00%              1,830,762,454       89.98%                      34,777
 19      Disapply pre-emption rights*                                                      1,796,085,428       98.35%             30,153,440                 1.65%              1,826,238,868       89.76%                  4,558,363
 20      Disapply pre-emption rights in connection with an acquisition or specified        1,773,062,102       97.09%             53,175,701                 2.91%              1,826,237,803       89.76%                  4,559,428
         capital investment*
 21      Authorise purchase of own shares*                                                 1,828,587,725       99.91%              1,634,548                 0.09%              1,830,222,273       89.96%                    574,958
 22      Call general meetings on 14 days' notice*                                         1,726,127,643       94.28%           104,652,489                  5.72%              1,830,780,132       89.98%                      17,099

 

*Special Resolution

NOTES:

1.   All resolutions were passed.

2.   Votes "For" and "Against" are expressed as a percentage of votes
received.

3.   A "Vote withheld" is not a vote in law and is not counted in the
calculation of the votes "For" or "Against" a resolution.

4.   Total number of shares in issue at close of business on 10 May 2022 was
2,034,572,935 shares.  89.88% of capital was voted.

5.   Computershare acted as scrutineer of the poll on all resolutions.

 

In accordance with Listing Rule 9.6.2, copies of the resolutions that do not
constitute ordinary business that were passed at the annual general meeting
have been submitted to the National Storage Mechanism and will be available
for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
 
 
 
 

AGM - Resolution Two

The Board notes the voting result in relation to Resolution 2 at today's
Annual General Meeting. We are grateful for the feedback and indications of
support received from shareholders in advance of the Meeting and will continue
to engage with shareholders who were unable to support this resolution, in
order to understand their views in advance of publishing an update statement
within six months of today. The Board also plans to engage with shareholders
later in the year on the Remuneration Policy which will be subject to approval
at the 2023 AGM.

Board Changes

As previously announced, Dr Regina Benjamin did not stand for re-election at
the AGM. Sharon O'Keefe has been appointed as ConvaTec's designated
Non-Executive Director for workforce engagement with effect from 13 May 2022.
This statement is made in accordance with Listing Rule 9.6.11.

Enquiries

Analysts and Investors

Kate Postans, Vice President, Investor Relations
                       +44 (0)7826 447
807
 

ir@convatec.com (mailto:ir@convatec.com)

 

Media

Buchanan: Charles Ryland / Chris Lane
            +44 (0)207 466 5000
 

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

 

About ConvaTec

ConvaTec is a global medical products and technologies company focused on
therapies for the management of chronic conditions, with leading market
positions in advanced wound care, ostomy care, continence and critical care,
and infusion care. ConvaTec's products provide a range of clinical and
economic benefits including infection prevention, protection of at-risk skin,
improved patient outcomes and reduced total cost of care. To learn more about
ConvaTec, please visit www.convatecgroup.com (http://www.convatecgroup.com/)
where a copy of this announcement can also be found.

 

 

 

 

# # #

END

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGUUAVRUBUVAAR